<DOC>
	<DOCNO>NCT02164734</DOCNO>
	<brief_summary>In study , newborn baby respiratory distress syndrome ( RDS ) , receive oxygen via nasal continuous airway pressure ( CPAP ) modality , need surfactant treatment randomize standard delivery surfactant via endotracheal tube airway ( inserted pre-medication pain short-acting narcotic ) , surfactant delivery via laryngeal mask airway ( LMA ) . The intent remove airway return baby non-invasive CPAP support , surfactant give . The primary outcome measure rate failure initial surfactant therapy . Standardized failure criterion reach : ) early , baby unable place back non-invasive CPAP ( i.e. , need tracheal intubation mechanical ventilation ) , b ) late , baby require ventilation , retreatment surfactant within 8 hour 2 dos surfactant . The objective protocol reduce need endotracheal intubation mechanical ventilation preterm neonates RDS need rescue surfactant therapy instill surfactant though LMA , achieve comparable efficacy surfactant treatment . The hypothesis surfactant treatment LMA decrease proportion baby RDS require mechanical ventilation subsequent intubation , compare standard surfactant treatment follow endotracheal intubation sedation .</brief_summary>
	<brief_title>Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway ( LMA ) Preterm Neonates With Respiratory Distress Syndrome</brief_title>
	<detailed_description>Respiratory Distress Syndrome ( RDS ) due deficiency pulmonary surfactant common preterm newborn . Early treatment surfactant improve oxygenation , reduces need subsequent mechanical ventilation , decrease incidence pulmonary air leak chronic lung disease also reduce mortality extremely premature newborn . Optimal treatment RDS include surfactant therapy avoidance invasive mechanical ventilation use nasal continuous positive airway pressure mode ( NCPAP NIPPV ) . The current standard method surfactant delivery require tracheal intubation least brief positive-pressure ventilation , INSURE ( Intubation-Surfactant-Extubation ) approach . Because tracheal intubation cause pain vagal-mediated physiologic instability neonate , premedication atropine narcotic recommend . However , narcotic premedication increase respiratory depression , may require sustained mechanical ventilation , thus contribute failure INSURE . In recent trial center , standard pretreatment morphine atropine associate failure INSURE 2/3 patient . Consequently , recently change standard premedication INSURE combination atropine remifentanil ( rapid onset , short-acting narcotic ) . The Laryngeal Mask Airway ( LMA ) commercially available , less invasive artificial airway need insert trachea ; FDA-approved use neonate ; preliminary data suggest use surfactant administration , trial associate low failure rate morphine plus INSURE approach . The main objective study protocol reduce need endotracheal intubation mechanical ventilation preterm neonates mild moderate RDS needing rescue surfactant therapy instill surfactant though LMA . A second objective compare efficacy surfactant administer via LMA versus endotracheal tube ( ETT ) decrease severity RDS . Additionally , evaluate safety surfactant administration via LMA . The primary hypothesis surfactant therapy deliver via LMA inferior surfactant therapy deliver via transient intubation ( INSURE technique ) short-acting narcotic premedication mild moderate RDS preterm neonate . This randomize controlled trial include baby mild-to-moderate RDS , less 48 hour age , gestational age 27 0/7 36 6/7 week , treat NCPAP ( NIPPV modality ) ≥ 5 cm H2O FiO2 0.30 0.60 least 2 hour maintain oxygen saturation pulse oximetry ( SpO2 ) 90-95 % . After informed consent obtain , baby randomly assign ( seal , opaque , consecutively numbered envelope ) , `` ETT '' `` LMA '' group . The `` ETT '' group manage accord current INSURE approach surfactant therapy ( endotracheal intubation follow premedication atropine + remifentanil ) , whereas `` LMA '' group pre-medicated atropine LMA insertion surfactant administration . Both group receive Infasurf ( 3mL/kg ) instill 2 aliquot via respective airway , follow PPV least 5 minute . The artificial airway remove patient return NCPAP/NIPPV 15 minute , spontaneous respiration adequate . Indications surfactant re-dosing mechanical ventilation equivalent group . Babies continue initiate assist ventilation via ETT follow occurs : - Persistent apnea ; - Severe retraction ; - Inability wean FiO2 &lt; 60 % Criteria re‐dosing surfactant : 1 . Within 8 hour first dose surfactant : • FiO2 20 % high baseline FiO2 , exclude obvious cause respiratory insufficiency pneumothorax . If early re‐dosing surfactant need patient either group , administer via ETT ( i.e. , LMA patient intubate , receive dose surfactant via ETT ) 2 . Beyond 8 hour first dose surfactant : - FiO2 ≥ 60 % , ; - FiO2 ≥ 30 % associate worsen clinical sign RDS . If late re‐dosing need patient LMA group , use LMA permit second dose . In ETT group , dose give via ETT .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<criteria>Mildtomoderate RDS ; Postnatal age 2 48 hour ; Gestational age 27 0/7 36 6/7 week ; Treated nasal CPAP modality ≥ 5 cm H2O FiO2 0.30 0.60 least 2 hour maintain SpO2 9095 % ; Informed consent Weight &lt; 800 g ; Airway anomalies ; Pulmonary air leak ; Craniofacial cardiothoracic malformation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>surfactant</keyword>
</DOC>